Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference
IMRX 11.27.2024
Date of Upcoming Event:2024-12-05
Name of Upcoming Event:Piper Sandler 36th Annual Healthcare Conference
About Gravity Analytica
Recent News
- 01.13.2025 - Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
- 01.07.2025 - Positive Phase 2a Data Update for IMM-1-104 in Pancreatic Cancer
- 01.07.2025 - Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms
Recent Filings
CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will present at the Piper Sandler 36thAnnual Healthcare Conference, which is taking place at the Lotte New York Palace in New York City from December 3-5, 2024, to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Chief Executive Officer, Harold “E.B.” Brakewood, Chief Business Officer and Mallory Morales, CPA, Chief Accounting Officer, Treasurer.
Format: Fireside Chat and 1x1 Investor Meetings
Date/Time: December 5 from 1:00 pm – 1:25 pm ET
The presentations will be webcast live and archived in the Investor Relations section of Immuneering’s website atEvents & Presentations | Immuneering Corporation.
About Immuneering Corporation
Immuneering is a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The Company aims to achieve universal activity through Deep Cyclic Inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering’s lead product candidate, IMM-1-104, is an oral, once-daily Deep Cyclic Inhibitor currently in a Phase 2a trial in patients with advanced solid tumors including those harboring RAS mutations. IMM-6-415 is an oral, twice-daily Deep Cyclic Inhibitor currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS or RAF mutations. The company’s development pipeline also includes several early-stage programs. For more information, please visitwww.immuneering.com.
Media Contact:Gina Nugentgina@nugentcommunications.com
Investor Contact:Laurence Watts619-916-7620laurence@newstreetir.com
